Spyre Therapeutics, Inc. SYRE Business Segments — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Spyre Therapeutics, Inc.’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s business segments — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s business segments — total revenue?
- Spyre Therapeutics, Inc. (SYRE) reported business segments — total revenue of $0 in Q4 2025.
- What is the long-term trend for Spyre Therapeutics, Inc.'s business segments — total revenue?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s business segments — total revenue has grown at a -100.0% compound annual growth rate (CAGR), from $2.33M to $0.
- What does business segments — total revenue mean?
- The total gross income generated by the segment from its primary business activities, such as licensing agreements, product sales, or research collaborations. It serves as the top-line indicator of the segment's market traction.